ANN ARBOR, Mich. Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.
In many poor countries, refrigerated conditions required for the current vaccines are costly and hard to come by. It's often difficult in the field to keep needles and syringes sterile. The need to have people return for the three shots currently required also limits success.
Now, a new vaccine that avoids these drawbacks has moved a step closer to human trials. Health researchers hope it will make it possible to immunize large numbers of children and adults in Africa, Asia and South America efficiently and safely.
Scientists at the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan report that a novel, needle-less method for getting an immunity-stimulating agent into the body has proved non-toxic and able to produce strong, sustained immune responses in animal studies. The vaccine is based on a super-fine emulsion of oil, water and surfactants placed in the nose.
The research was supported by the Grand Challenges in Global Health initiative, which is funded by the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health, the Wellcome Trust and the Canadian Institutes of Health Research. The findings appear online in the journal PLoS ONE.
The nanoemulsion represents a new delivery method for an antigen already used in existing hepatitis B vaccines to activate the body's immune defenses.
"Our results indicate that needle-free nasal immunization, using a combination of nanoemulsion and hepatitis B antigen, could be a safe and effective hepatitis B vaccine, and also provide an alternat
'/>"/>
| Contact: Anne Rueter arueter@umich.edu 734-764-2220 University of Michigan Health System Source:Eurekalert |